arrow
J

Jennifer J. Huang

university of washington
H指数:17
被引数:1,046

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia

绝对淋巴细胞计数单一进展在慢性淋巴细胞白血病中的发生率和临床影响

2026-09-010
PRE
Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma

滤泡性淋巴瘤中,嵌合抗原受体T细胞疗法后双特异性抗体疗法的真实世界结局

2026-06-180
OAAI
Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome

早期神经系统反应预测anakinra治疗免疫效应细胞相关神经毒性综合征的结局

2026-06-020
OAAI
Real-World Outcomes and Toxicities of CAR-T in Relapsed/Refractory Follicular Lymphoma: A Multicenter Cohort Study

真实世界CAR-T治疗复发/难治性滤泡性淋巴瘤的疗效和毒性:一项多中心队列研究

2026-03-020
OAAI
Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma

髓外疾病与多发性骨髓瘤中B细胞成熟抗原CAR T细胞疗法后的严重毒性与相关。

2025-12-015
OA
Opportunities to improve antibiotic stewardship, and identification of blood biomarkers associated with bacteremia following CAR-T cell therapy

改善抗生素合理使用的机会,以及CAR-T细胞疗法后菌血症相关血液生物标志物的鉴定

2025-07-310
PRE
Corrigendum to Active Extramedullary Disease Predicts ICANS and Early ICAHT after CAR-T Therapy in Multiple Myeloma Transplantation and Cellular Therapy 31/2S (2025) S409

更正:活动性髓外病变预测CAR-T疗法后多发性骨髓瘤移植与细胞治疗中的ICANS和早期ICAHT 《移植与细胞治疗》31/2S (2025) S409

2025-04-120
PRE
Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers

评估商业用Axicabtagene Ciloleucel(axi-cel)和Tisagenlecleucel(tisa-cel)治疗复发或难治性(R/R)滤泡性淋巴瘤(FL)的结局和毒性的研究:来自10家美国学术中心的真实世界证据(RWE)

BLOOD
IF23.1
2024-11-050
PRE
Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL- the Avenue-2 Trial

Acalabrutinib和Venetoclax(AV)联合治疗经治CLL/SLL患者2年——Avenue-2试验

BLOOD
IF23.1
2024-11-050
PRE
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL

与CD19 CAR T细胞治疗复发/难治性CLL的长期结果相关的因素

2023-11-177
OAAI